In some studies, researchers may want to detect the presence of microbial strains in samples over time. This tracking of strains is important, for example, in determining whether a probiotic strain persists in the gut or whether strains from a fecal microbiota transplant have stably engrafted in their new environment. Many analysis pipelines, however, do not provide sufficient resolution to detect strains (or bacterial clones), which reduces confidence in determining whether the exact strains of interest are present over time.
Clinical Microbiomics offers its Clonal-level Microbiome Profiling pipeline, providing the most sensitive and accurate microbiome profiling in the field. With Clonal-level Microbiomics™️, we resolve clonal populations (i.e. strains) found in samples using single nucleotide differences, and use phylogeny to relate them to each other and build trees. The pipeline can resolve strains with an average nucleotide identity (ANI) of 99.9%. This method also enables us to link host or microbial traits to clades (phylogenetic groups) within microbial populations, and even to mine the genes behind the functional differences.
Fecal microbiota transplantation (FMT) from a donor is an effective treatment for individuals with recurrent Clostridioides difficile infection (CDI). The donor FMT population often engrafts in the recipient, but only with high-resolution microbiome analysis is it possible to determine whether the exact strains from the donor are present in the recipient or in another environment. If researchers observe highly similar strains (or clones) in multiple environments, the likelihood is high that transfer has occurred from one environment to another.
The Clinical Microbiomics team collaborated with researchers from the Technical University of Denmark and the Aarhus University Hospital on a project that aimed to determine whether strains of bacteria introduced to a pregnant individual through an FMT intervention were transferred to her healthy infant born 26 weeks later.
The case report describes a detailed analysis that aimed to discover whether bacterial strain transfer occurred from the FMT donor to the pregnant mother, and further, to her infant born at term. The mother developed CDI during pregnancy and was treated successfully with a single dose of FMT before giving vaginal birth at term to a healthy infant. For the analysis, fecal samples were collected from all three individuals: the FMT donor; the mother at several time points (before FMT, and 1, 8, 15, 22, 26, and 50 weeks after FMT); and the infant at several time points (meconium at birth and 3 & 6 months after birth).
Samples were analyzed using Clinical Microbiomics’ Clonal-level Microbiomics™️ platform. Single nucleotide variants were identified in the metagenomic samples and were compared to a collection of samples from healthy infants and adults. Two forms of engraftment profiling were used, allowing researchers to track microbial populations from FMT donor to recipient—despite the recipient already having closely-related endogenous strains.
Results showed that, before receiving FMT, the pregnant mother’s gut microbiota was characterized by low diversity and the presence of potential pathogens. Upon receiving FMT, these features diminished. After the infant’s birth, the precise bacterial strains administered to the mother via FMT were found in the infant, suggesting both persistence over time and cross-generational transfer of the strains.
This case study demonstrates the potential to track precise strains from one environment to another with confidence, and to determine the persistence of these strains over time. Vertical transfer of bacterial strains from a pregnant mother to an infant was observed, demonstrating a potential route for influencing the infant gut microbiota.
Let’s find the answers. Let our expert scientists guide you. Contact us to discuss your study design and research needs on engraftment and strain tracking.